查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474029

頭頸鱗狀細胞癌的細胞療法 - 研發管線分析：2024 年

Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics 2024
出版日期: | 出版商: Mellalta Meets LLP | 英文 109 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

過繼性細胞療法（ACT）在多種癌症的早期試驗中顯示出有希望的結果。然而，治療頭頸鱗狀細胞癌（HNSCC）的成功方法面臨實體瘤常見的獨特課題。這些課題包括需要為 T 細胞建立適當的歸巢機制，以有效地靶向腫瘤，確保腫瘤內有足夠的 T 細胞浸潤以產生強大的免疫反應，並且這包括識別不會對腫瘤產生影響的抗原。儘管 ACT 治療 HNSCC 仍處於起步階段，但人們樂觀地認為，它將在不久的將來在治療中發揮重要作用。這與檢查點抑制劑合併用於化療難治性患者和復發轉移的第一線治療具有潛力。

根據我們的分析，正在開發的細胞療法有多種可以幫助治療 HNSCC，包括 TCR T 細胞療法、腫瘤浸潤淋巴細胞 (TIL) 以及與免疫檢查點抑制劑 (ICIs) 的聯合療法。

本報告探討了頭頸鱗狀細胞癌的細胞療法，包括市場機會、關鍵競爭分析、公司管道藥物概況、臨床試驗和其他進展。

目錄

第一章 報告概述

第2章 頭頸鱗狀細胞癌（HNSCC）細胞治療標靶背景

  • 頭頸部鱗狀細胞癌 (HNSCC) 的過繼性細胞療法
  • 過繼細胞療法的類型
  • 頭頸鱗狀細胞癌的CAR-T療法
  • CAR-NK細胞治療頭頸鱗狀細胞癌
  • TCR T細胞治療頭頸鱗狀細胞癌
  • TIL治療頭頸鱗狀細胞癌

第三章 頭頸鱗狀細胞癌（HNSCC）細胞治療的管線分析

第四章臨床試驗與研究

  • 頭頸鱗狀細胞癌的細胞療法臨床試驗（依地區）
  • HNSCC細胞治療單藥治療及合併治療臨床試驗
  • 臨床和監管時間表
  • 後期概況比較概述

第五章授權、收購和合作

第六章 管道情況

  • HNSCC 管道中細胞療法的藥物概況 - 概述
  • 第二階段
  • 一期/二期
  • 第一階段
  • 臨床前
  • 藥物發現

第7章 HNSCC細胞治療的SWOT分析

第8章附錄

簡介目錄

The Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 17+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, cell therapy modalities, and intervention type. Cell Therapies in Head and Neck Squamous Cell Carcinoma-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Adoptive cell therapies (ACT) have demonstrated promising outcomes in early-stage trials across various cancers. However, successful approaches in treating HNSCC face specific challenges commonly found in solid tumors. These challenges include the necessity to establish appropriate homing mechanisms for T cells to effectively target the tumor, ensuring adequate T-cell infiltration into the tumor for a robust immune response, and identifying antigens that will not lead to off-tumor effects. While ACT approaches are still in their early stages for HNSCC, there is optimism that they will soon play a significant role in treatment. This may involve potential combinations with checkpoint inhibitors for patients with chemotherapy-refractory disease and potentially in the first-line recurrent metastatic setting.

In this report, Mellalta Meets provides an in-depth analysis of the Cell Therapies in the HNSCC Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidates in the Cell Therapies in the HNSCC Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Iovance Biotherapeutics, ImmunityBio, Rapa Therapeutics, TCRCure Biopharma, Immatics, and many more which have a robust clinical pipeline of cell therapy candidates for HNSCC.

As per analysis, the development pipeline is full of different cell therapy modalities like TCR T-cell therapies, tumor-infiltrating lymphocytes (TILs), and combination approaches with immune checkpoint inhibitors (ICI) which can help in addressing HNSCC.

Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights

There are 5 products in the Phase 2 and Phase 1/2 stage of development, representing 15% of the total share of the developing Cell Therapies in HNSCC.

The HNSCC cell therapies landscape is dominated by Phase 1 stage assets accounting for 54.55% followed by Discovery stage products which account for 24.24%.

To be continued...

Report Coverage:

Indication Prioritization: HNSCC market potential

Business Transactions & Strategies: Key collaborations and deal values

HNSCC Cell Therapies Pipeline Development: Product Profiles, Clinical Trials & Results

HNSCC Cell Therapies Acquisition Targets

HNSCC Cell Therapies Competitive Intelligence

Recent and upcoming events

Table of Content

1.Report Overview

2.The Cell Therapies in HNSCC Target Background

  • 2.1.Adoptive Cell Therapies in HNSCC
  • 2.2.Types of Adoptive Cell Therapies
  • 2.3.CAR-T Therapy in HNSCC
  • 2.4.CAR-NK cell therapy in HNSCC
  • 2.5.TCR T-cell therapy in HNSCC
  • 2.6.TIL Therapy in HNSCC

3.Cell Therapies in HNSCC Pipeline Analysis

  • 3.1.Development Overview
  • 3.2.Pipeline Products by Stage of Development
  • 3.3.Cell Therapies in HNSCC Competitive Landscape
  • 3.4.Pipeline Products by Company and Region
  • 3.5.Type of Cell Therapies in HNSCC Pipeline Landscape

4.Clinical Trials and Research

  • 4.1.Cell Therapies Clinical Trials in HNSCC by Region
  • 4.2.HNSCC Cell therapies Monotherapy & Combinations Clinical Trials
  • 4.3.Clinical & Regulatory Timelines
  • 4.4.Late-Stage Profiles Comparisons At-a-glance

5.Licensing, Acquisition, and Collaboration

  • 5.1.Cell Therapies in HNSCC Licensing, Acquisition, and Deal Values
  • 5.2.Licensing by Transaction Type and Total Amount Size by Phases

6.Pipeline Landscape

  • 6.1.Cell Therapies in HNSCC Pipeline Drug Profiles- at a glance
  • 6.2.Phase II
    • 6.2.1.LN-145
      • 6.2.1.1.Product Profile
      • 6.2.1.2.Clinical Trial Details
    • 6.2.2.PD-L1 T-haNK
      • 6.2.2.1.Product Profile
      • 6.2.2.2.Clinical Trial Details
  • 6.3.Phase I/II
    • 6.3.1.RAPA-201
      • 6.3.1.1.Product Profile
      • 6.3.1.2.Clinical Trial Details
    • 6.3.2.EBV TCR-T
      • 6.3.2.1.Product Profile
      • 6.3.2.2.Clinical Trial Details
    • 6.3.3.IMA402
      • 6.3.3.1.Product Profile
      • 6.3.3.2.Clinical Trial Details
  • 6.4.Phase I
    • 6.4.1.HRYZ-T101
      • 6.4.1.1.Product Profile
      • 6.4.1.2.Clinical Trial Details
    • 6.4.2.TSC-200-A0201
      • 6.4.2.1.Product Profile
      • 6.4.2.2.Clinical Trial Details
    • 6.4.3.P-MUC1C-ALLO1
      • 6.4.3.1.Product Profile
      • 6.4.3.2.Clinical Trial Details
    • 6.4.4.NT-175
      • 6.4.4.1.Product Profile
      • 6.4.4.2.Clinical Trial Details
    • 6.4.5.TSC-201-B0702
      • 6.4.5.1.Product Profile
      • 6.4.5.2.Clinical Trial Details
    • 6.4.6.Uzatresgene autoleucel
      • 6.4.6.1.Product Profile
      • 6.4.6.2.Clinical Trial Details
    • 6.4.7.TSC-203-A0201
      • 6.4.7.1.Product Profile
      • 6.4.7.2.Clinical Trial Details
    • 6.4.8.TSC-204-A0201
      • 6.4.8.1.Product Profile
      • 6.4.8.2.Clinical Trial Details
    • 6.4.9.TSC-204-C0702
      • 6.4.9.1.Product Profile
      • 6.4.9.2.Clinical Trial Details
    • 6.4.10.TSC-204-A0101
      • 6.4.10.1.Product Profile
      • 6.4.10.2.Clinical Trial Details
    • 6.4.11.TBio-4101
      • 6.4.11.1.Product Profile
      • 6.4.11.2.Clinical Trial Details
    • 6.4.12.CRTE7A2
      • 6.4.12.1.Product Profile
      • 6.4.12.2.Clinical Trial Details
    • 6.4.13.AGX-148
      • 6.4.13.1.Product Profile
      • 6.4.13.2.Clinical Trial Details
    • 6.4.14.NEXI-003
      • 6.4.14.1.Product Profile
      • 6.4.14.2.Clinical Trial Details
    • 6.4.15.IMA401
      • 6.4.15.1.Product Profile
      • 6.4.15.2.Clinical Trial Details
    • 6.4.16.WU-NK-101
      • 6.4.16.1.Product Profile
      • 6.4.16.2.Clinical Trial Details
    • 6.4.17.IMA203
      • 6.4.17.1.Product Profile
      • 6.4.17.2.Clinical Trial Details
    • 6.4.18.IMA-203CD8
      • 6.4.18.1.Product Profile
      • 6.4.18.2.Clinical Trial Details
  • 6.5.Preclinical
    • 6.5.1.ADP-600
    • 6.5.2.IMA204
  • 6.6.Discovery
    • 6.6.1.TSC-200-C0702
    • 6.6.2.TSC-201-A0201
    • 6.6.3.TSC-201-A2402
    • 6.6.4.TSC-202-A0201
    • 6.6.5.TSC-203-B0702
    • 6.6.6.TSC-204-A0301
    • 6.6.7.TSC-204-B0702
    • 6.6.8.TSC-203-A2402

7.Cell Therapies in HNSCC SWOT Analysis

8.Appendix

  • 8.1.About us